HomeAbout UsNewsContact Us
Jan 21, 2012
CUBRC Awarded BARDA Contract Worth up to $67M
Oct 11, 2011
CUBRC Awarded $36 Million NIAID Contract
Jul 13, 2011
Michael Holden to Receive AIAA Honor
May 25, 2011
MILITARY $725,000 Federal Contract Awarded CUBRC
May 17, 2011
CUBRC Inc. awarded $562,245 Federal contract
News & Events
January 21, 2012 « Back To News
CUBRC Awarded BARDA Contract Worth up to $67M

Buffalo, NY - January 20, 2012 - CUBRC, Inc.’s President and CEO, Tom McMahon announced today that CUBRC’s Biological and Medical Sciences team, in collaboration with Tetraphase Pharmaceuticals, Inc. , has received a five-year contract worth up to $67 million from the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR), within the Department of Health and Human Services (DHHS). CUBRC and Tetraphase will be developing, manufacturing and clinically evaluating a novel broad-spectrum tetracycline antibiotic for respiratory diseases caused by biothreat and antibiotic-resistant public health pathogens. Mr. McMahon stated, “We are truly thankful for BARDA’s confidence in our proposal to develop the next generation of treatments for bacterial infections.”
Today’s research and drug development programs for the treatment of diseases from biological threats emphasize broad-spectrum therapeutics effective against multiple types of infections instead of a single disease.

CUBRC will be leveraging its technical expertise in Biomedical-related R&D and its experience leading large federal government contracts to collaborate with Tetraphase to jointly execute key development, manufacturing, preclinical and clinical activities to position the drug candidate known as TP-434, which was discovered and patented by Tetraphase, for further development against important biothreat agents including Francisella tularensis, which causes tularemia, Yersinia pestis, which causes plague, and Bacillus anthracis, which causes anthrax disease, as well as bacterial pathogens associated with community-acquired bacterial pneumonia and other serious hospital infections. The contract has been awarded with a 12-month base period with committed funding of $11.5 million and subsequent options that, when exercised, could bring the total value of the contract award to almost $67 million.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com

For BARDA’s related press announcement, please go to


Professional Services | Public Health & Safety | Medical Biotechnology | Chemical & Biological Defense | Information Exploitation | Hypersonics
Home | About Us | News | Contact Us ©2014CUBRC. All Rights Reserved Produced By VertaSource